O
Oliver Basu
Researcher at Boston Children's Hospital
Publications - 18
Citations - 836
Oliver Basu is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Transplantation & Bone marrow. The author has an hindex of 10, co-authored 16 publications receiving 774 citations.
Papers
More filters
Journal ArticleDOI
Peripheral Blood Stem Cell Transplantation From Unrelated Donors: A Comparison With Marrow Transplantation
O Ringdén,Mats Remberger,Volker Runde,Martin Bornhäuser,I. W. Blau,Nadezda Basara,Kristina Hölig,D. W. Beelen,Hans Hägglund,Oliver Basu,G. Ehninger,Axel A. Fauser +11 more
TL;DR: Peripheral blood stem cell (PBSC) transplants from HLA-A, -B, and -DR compatible unrelated donors (n = 45) were compared with bone marrow (BM; BM group, n = 45).
Journal ArticleDOI
Adenoviral infection after allogeneic stem cell transplantation (SCT): report on 130 patients from a single SCT unit involved in a prospective multi center surveillance study
V Runde,S Ross,Rudolf Trenschel,E Lagemann,Oliver Basu,K Renzing-Köhler,Ulrich W. Schaefer,Michael Roggendorf,Ernst Holler +8 more
TL;DR: It is demonstrated that a positive AV antibody test in the donor is an important risk factor for AV infection after allogeneic SCT, in addition to well-known risk factors for viral infection after SCT.
Journal ArticleDOI
Transplantation of Filgrastim-Mobilized Peripheral Blood Stem Cells From HLA-Identical Sibling or Alternative Family Donors in Patients With Hematologic Malignancies: A Prospective Comparison on Clinical Outcome, Immune Reconstitution, and Hematopoietic Chimerism
Dietrich W. Beelen,Helmut Ottinger,Ahmet H. Elmaagacli,Birgit Scheulen,Oliver Basu,Bernhard Kremens,Werner Havers,Hans Grosse-Wilde,Ulrich W. Schaefer +8 more
TL;DR: Monthly monitoring of peripheral blood T-helper cell subsets, B cells, and monocytes during the first year posttransplantation showed a nearly identical course of immune cell reconstitution in both patient subsets.
Journal ArticleDOI
Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM).
Peter Bader,Zyrafete Kuçi,Shahrzad Bakhtiar,Oliver Basu,Gesine Bug,Mike Dennis,Johann Greil,Aniko Barta,Krisztián M. Kállay,Peter Lang,Giovanna Lucchini,Raj Pol,A. Schulz,Karl-Walter Sykora,Irene von Luettichau,Grit Herter-Sprie,Mohammad Ashab Uddin,Phil Jenkin,Abdulrahman Alsultan,Jochen Buechner,Jerry Stein,Agnes Kelemen,Andrea Jarisch,Jan Soerensen,Emilia Salzmann-Manrique,Martin Hutter,Richard Schäfer,Erhard Seifried,Thomas Klingebiel,Halvard Bonig,Selim Kuçi +30 more
TL;DR: This novel MSC manufacturing protocol characterized by high in vitro potency and near-identity of individual doses was effective in children and adults, suggesting that MSC-FFM represents a promising therapy for steroid refractory aGvHD.
Journal ArticleDOI
Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey.
Zyrafete Kuçi,Halvard Bonig,Hermann Kreyenberg,Milica Bunos,Anna Jauch,Johannes W.G. Janssen,Marijana Skific,Kristina Michel,Ben Eising,Giovanna Lucchini,Shahrzad Bakhtiar,Johann Greil,Peter Lang,Oliver Basu,Irene von Luettichau,A. Schulz,Karl-Walter Sykora,Andrea Jarisch,Jan Soerensen,Emilia Salzmann-Manrique,Erhard Seifried,Thomas Klingebiel,Peter Bader,Selim Kuçi +23 more
TL;DR: Mesenchymal stromal cell end-products may, therefore, provide a novel therapeutic tool for the effective treatment of severe acute graft-versus-host disease.